|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.09 USD | +3.54% |
|
+3.02% | -14.79% |
| Apr. 15 | Sector Update: Health Care Stocks Gain Monday Afternoon | MT |
| Apr. 15 | Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... |  |
Nov 26 (Reuters) - Novavax Inc:
* NOVAVAX INC - HAS ALREADY INITIATED DEVELOPMENT OF A NEW RECOMBINANT SPIKE PROTEIN BASED ON THE KNOWN GENETIC SEQUENCE OF B.1.1.529
* NOVAVAX - WILL HAVE NEW RECOMBINANT SPIKE PROTEIN BASED ON KNOWN GENETIC SEQUENCE OF B.1.1.529 READY FOR TESTING, MANUFACTURING WITHIN NEXT FEW WEEKS
* NOVAVAX - RECENT DATA FROM PHASE 2 TRIAL LEAD US TO BELIEVE THAT OUR VACCINE IS LIKELY TO PROVIDE PROTECTION AGAINST NEW, EMERGING COVID-19 VARIANTS Further company coverage:
| 1st Jan change | Capi. | |
|---|---|---|
| -14.79% | 572M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
NOVAVAX, INC. 
